Acetylator phenotypes in rheumatoid arthritis patients with or without adverse drug reactions to sodium-aurothiomalate or d-penicillamine.
The acetylator phenotype was determined in 59 patients with classical, seropositive and erosive rheumatoid arthritis (RA) treated with sodium-aurothiomalate or d-penicillamine. Patients with adverse drug reactions (ADR) leading to drug withdrawal (n = 29) were compared with a group of patients without ADR (n = 30). The frequency of slow acetylators was significantly (p less than 0.05) increased in all RA patients, irrespective of the presence of ADR, particularly in the male patients, compared with a control population. No association was found between acetylator phenotype and clinical data or secondary Sjögrens's syndrome (SS).
D000107:Acetylation; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics*; D002851:Chromatography, High Pressure Liquid; D003622:Dapsone / Q000378:metabolism; D005260:Female; D006052:Gold Sodium Thiomalate / Q000009:adverse effects* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000009:adverse effects* / Q000378:metabolism; D010641:Phenotype
D006052:Gold Sodium Thiomalate; D003622:Dapsone; D010396:Penicillamine